In the 200 mg sonidegib group , 18 ( 43 % , 95 % CI 28-59 ) patients who achieved an objective response , as assessed by central review , were noted among the 42 with locally advanced basal cell carcinoma and two ( 15 % , 2-45 ) among the 13 with metastatic disease .